Orthofix Medical (NASDAQ:OFIX) Major Shareholder Engine Capital Management, Lp Purchases 112,950 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Engine Capital Management, Lp bought 112,950 shares of Orthofix Medical stock in a transaction on Tuesday, May 5th. The shares were purchased at an average cost of $11.99 per share, for a total transaction of $1,354,270.50. Following the completion of the purchase, the insider directly owned 3,783,131 shares of the company’s stock, valued at $45,359,740.69. This trade represents a 3.08% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

• On Thursday, May 7th, Engine Capital Management, Lp bought 30,000 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.18 per share, for a total transaction of $365,400.00.
• On Wednesday, May 6th, Engine Capital Management, Lp bought 41,946 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.23 per share, for a total transaction of $512,999.58.
• On Wednesday, February 25th, Engine Capital Management, Lp bought 13,061 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.96 per share, for a total transaction of $169,270.56.
• On Tuesday, February 24th, Engine Capital Management, Lp purchased 124,797 shares of Orthofix Medical stock. The stock was bought at an average cost of $12.55 per share, for a total transaction of $1,566,202.35.

Orthofix Medical Price Performance

Orthofix Medical stock opened at $12.07 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.43 and a current ratio of 2.87. The company has a market capitalization of $484.49 million, a price-to-earnings ratio of -7.99 and a beta of 0.79. The company’s 50 day simple moving average is $12.20 and its 200-day simple moving average is $13.88. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $16.99.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.16. The firm had revenue of $196.71 million during the quarter, compared to analysts’ expectations of $196.40 million. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. As a group, equities research analysts expect that Orthofix Medical Inc. will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Orthofix Medical

Several large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP increased its stake in Orthofix Medical by 0.7% during the 2nd quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company’s stock worth $41,497,000 after buying an additional 26,769 shares during the period. Juniper Investment Company LLC increased its stake in Orthofix Medical by 23.3% during the 4th quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company’s stock worth $53,217,000 after buying an additional 663,278 shares during the period. Paradigm Capital Management Inc. NY increased its stake in Orthofix Medical by 34.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after buying an additional 858,900 shares during the period. Armistice Capital LLC increased its stake in Orthofix Medical by 18.4% during the 4th quarter. Armistice Capital LLC now owns 2,648,000 shares of the medical device company’s stock worth $40,144,000 after buying an additional 412,000 shares during the period. Finally, Millennium Management LLC increased its stake in Orthofix Medical by 86.6% during the 3rd quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after buying an additional 684,850 shares during the period. 89.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OFIX has been the topic of a number of research analyst reports. Barrington Research reissued an “outperform” rating and issued a $17.00 target price on shares of Orthofix Medical in a research report on Friday, April 10th. Canaccord Genuity Group cut their target price on Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. TD Cowen initiated coverage on Orthofix Medical in a research report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 target price on the stock. Wall Street Zen lowered Orthofix Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Stifel Nicolaus cut their target price on Orthofix Medical from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.25.

Key Orthofix Medical News

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a >10% holder) accumulated ~184,900 OFIX shares across May 5–7 (~112,950 @ $11.99, 41,946 @ $12.23, 30,000 @ $12.18), spending roughly $2.23M and raising its stake to ~3.85M shares (≈+4.98% total increase). The buy program signals confidence from a large shareholder and can be viewed as supportive for the stock. Read More.
• Positive Sentiment: Q1 results beat modestly: Orthofix reported EPS of ($0.52) vs. consensus ($0.68) and revenue $196.7M roughly in line with estimates. The beat reduces near-term downside risk from guidance misses, though the company remains unprofitable with negative margins and ROE. Read More.
• Neutral Sentiment: Q1 earnings call transcript is available for detail on trends, margin drivers and outlook — useful for investors assessing whether the beat reflects sustainable improvement or one-offs. Read More.
• Negative Sentiment: Regulatory risk: the FDA reclassified bone growth stimulators (Orthofix’s core product area), which may raise competition and pressure margins going forward. This is a material industry/regulatory change that could weigh on revenue and profitability if reimbursement or market dynamics shift. Read More.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.